WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 462187
CAS#: 2056261-41-5
Description: BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor. BRD0705 can be used for acute myeloid leukemia.
MedKoo Cat#: 462187
Name: BRD0705
CAS#: 2056261-41-5
Chemical Formula: C20H23N3O
Exact Mass: 321.1841
Molecular Weight: 321.424
Elemental Analysis: C, 74.74; H, 7.21; N, 13.07; O, 4.98
Synonym: BRD0705; BRD-0705; BRD 0705;
IUPAC/Chemical Name: (S)-4-ethyl-7,7-dimethyl-4-phenyl-1,2,4,6,7,8-hexahydro-5H-pyrazolo[3,4-b]quinolin-5-one
InChi Key: NCKLQXXBRWCYMA-FQEVSTJZSA-N
InChi Code: InChI=1S/C20H23N3O/c1-4-20(13-8-6-5-7-9-13)14-12-21-23-18(14)22-15-10-19(2,3)11-16(24)17(15)20/h5-9,12H,4,10-11H2,1-3H3,(H2,21,22,23)/t20-/m0/s1
SMILES Code: O=C1CC(C)(C)CC2=C1[C@@](CC)(C3=CC=CC=C3)C4=CNNC4=N2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 321.424 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Wagner FF, Benajiba L, Campbell AJ, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018;10(431):eaam8460. doi:10.1126/scitranslmed.aam8460.
